Abstract
Developing antiviral drugs, vaccines and diagnostic markers is still the most ambitious challenge in clinical virology. In the past few decades, data from high-throughput technologies have allowed for the rapid development of new antiviral therapeutic strategies, thus making a profound impact on translational research. Most of the current preclinical studies in virology are aimed at evaluating the dynamic composition and localization of the protein platforms involved in various host-virus interactions. Among the different possible approaches, mass spectrometry-based proteomics is increasingly being used to define the protein composition in subcellular compartments, quantify differential protein expression among samples, characterize protein complexes, and analyse protein post-translational modifications. Here, we review the current knowledge of the most useful proteomic approaches in the study of viral persistence and pathogenicity, with a particular focus on recent advances in hepatitis C research.
| Original language | English |
|---|---|
| Pages (from-to) | 23-28 |
| Number of pages | 6 |
| Journal | Clinical Microbiology and Infection |
| Volume | 19 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 2013 |
Fingerprint
Keywords
- Biomarker discovery
- HCV
- Mass spectrometry
- Post-translational modifications
- Proteomics
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases
Cite this
Applying proteomic technology to clinical virology. / Mancone, C.; Ciccosanti, F.; Montaldo, C.; Perdomo, A. B.; Piacentini, M.; Alonzi, T.; Fimia, G. M.; Tripodi, M.
In: Clinical Microbiology and Infection, Vol. 19, No. 1, 01.2013, p. 23-28.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Applying proteomic technology to clinical virology
AU - Mancone, C.
AU - Ciccosanti, F.
AU - Montaldo, C.
AU - Perdomo, A. B.
AU - Piacentini, M.
AU - Alonzi, T.
AU - Fimia, G. M.
AU - Tripodi, M.
PY - 2013/1
Y1 - 2013/1
N2 - Developing antiviral drugs, vaccines and diagnostic markers is still the most ambitious challenge in clinical virology. In the past few decades, data from high-throughput technologies have allowed for the rapid development of new antiviral therapeutic strategies, thus making a profound impact on translational research. Most of the current preclinical studies in virology are aimed at evaluating the dynamic composition and localization of the protein platforms involved in various host-virus interactions. Among the different possible approaches, mass spectrometry-based proteomics is increasingly being used to define the protein composition in subcellular compartments, quantify differential protein expression among samples, characterize protein complexes, and analyse protein post-translational modifications. Here, we review the current knowledge of the most useful proteomic approaches in the study of viral persistence and pathogenicity, with a particular focus on recent advances in hepatitis C research.
AB - Developing antiviral drugs, vaccines and diagnostic markers is still the most ambitious challenge in clinical virology. In the past few decades, data from high-throughput technologies have allowed for the rapid development of new antiviral therapeutic strategies, thus making a profound impact on translational research. Most of the current preclinical studies in virology are aimed at evaluating the dynamic composition and localization of the protein platforms involved in various host-virus interactions. Among the different possible approaches, mass spectrometry-based proteomics is increasingly being used to define the protein composition in subcellular compartments, quantify differential protein expression among samples, characterize protein complexes, and analyse protein post-translational modifications. Here, we review the current knowledge of the most useful proteomic approaches in the study of viral persistence and pathogenicity, with a particular focus on recent advances in hepatitis C research.
KW - Biomarker discovery
KW - HCV
KW - Mass spectrometry
KW - Post-translational modifications
KW - Proteomics
UR - http://www.scopus.com/inward/record.url?scp=84871589640&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84871589640&partnerID=8YFLogxK
U2 - 10.1111/1469-0691.12029
DO - 10.1111/1469-0691.12029
M3 - Article
C2 - 23034105
AN - SCOPUS:84871589640
VL - 19
SP - 23
EP - 28
JO - Clinical Microbiology and Infection
JF - Clinical Microbiology and Infection
SN - 1198-743X
IS - 1
ER -